Summary
Boston Scientific Corporation (BSX) filed an 8-K on November 6, 2007, reporting two significant events. First, effective November 1, 2007, the company approved an amended and restated Severance Pay and Layoff Notification Plan, outlining severance benefits, outplacement services, and continuation of health and life insurance for eligible U.S. employees who are involuntarily terminated under specific circumstances. This plan includes provisions for eligible executive officers. More significantly for investors, on November 5, 2007, BSX announced a definitive agreement to sell its Cardiac Surgery and Vascular Surgery businesses to Getinge Group for $750 million in cash. This divestiture is expected to close within 45 to 90 days, pending regulatory approvals and customary closing conditions. This strategic move signals a potential shift in BSX's business focus.
Key Highlights
- 1Boston Scientific Corporation (BSX) entered into a definitive agreement to sell its Cardiac Surgery and Vascular Surgery businesses to Getinge Group for $750 million in cash.
- 2The sale is expected to close within 45 to 90 days, subject to regulatory approvals and customary conditions.
- 3The company approved an amended and restated Severance Pay and Layoff Notification Plan for eligible U.S. employees, effective November 1, 2007.
- 4The severance plan provides benefits including severance pay, outplacement services, and continuation of health and life insurance.
- 5The severance plan is applicable to eligible executive officers under specified involuntary termination circumstances.
- 6The divestiture represents a significant strategic decision by BSX, potentially refocusing its operations.